164 related articles for article (PubMed ID: 8985357)
21. Sequence requirements of the Epstein-Barr virus latent origin of DNA replication.
Harrison S; Fisenne K; Hearing J
J Virol; 1994 Mar; 68(3):1913-25. PubMed ID: 8107251
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation.
Harada S; Kieff E
J Virol; 1997 Sep; 71(9):6611-8. PubMed ID: 9261383
[TBL] [Abstract][Full Text] [Related]
23. Transcription of the Epstein-Barr virus nuclear antigen 1 (EBNA1) gene occurs before induction of the BCR2 (Cp) EBNA gene promoter during the initial stages of infection in B cells.
Schlager S; Speck SH; Woisetschläger M
J Virol; 1996 Jun; 70(6):3561-70. PubMed ID: 8648690
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa.
Robertson ES; Grossman S; Johannsen E; Miller C; Lin J; Tomkinson B; Kieff E
J Virol; 1995 May; 69(5):3108-16. PubMed ID: 7707539
[TBL] [Abstract][Full Text] [Related]
25. Unique Epstein-Barr virus (EBV) latent gene expression, EBNA promoter usage and EBNA promoter methylation status in chronic active EBV infection.
Yoshioka M; Kikuta H; Ishiguro N; Ma X; Kobayashi K
J Gen Virol; 2003 May; 84(Pt 5):1133-1140. PubMed ID: 12692278
[TBL] [Abstract][Full Text] [Related]
26. DNA-binding studies of the Epstein-Barr virus nuclear antigen 2 (EBNA-2): evidence for complex formation by latent membrane protein gene promoter-binding proteins in EBNA-2-positive cell lines.
Sauder C; Haiss P; Grässer FA; Zimber-Strobl U; Mueller-Lantzsch N
J Gen Virol; 1994 Nov; 75 ( Pt 11)():3067-79. PubMed ID: 7964616
[TBL] [Abstract][Full Text] [Related]
27. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus.
Sung NS; Kenney S; Gutsch D; Pagano JS
J Virol; 1991 May; 65(5):2164-9. PubMed ID: 1850003
[TBL] [Abstract][Full Text] [Related]
28. Latency pattern of Epstein-Barr virus and methylation status in Epstein-Barr virus-associated hemophagocytic syndrome.
Yoshioka M; Kikuta H; Ishiguro N; Endo R; Kobayashi K
J Med Virol; 2003 Jul; 70(3):410-9. PubMed ID: 12767005
[TBL] [Abstract][Full Text] [Related]
29. High-resolution analysis of CpG methylation and in vivo protein-DNA interactions at the alternative Epstein-Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1.
Bakos A; Banati F; Koroknai A; Takacs M; Salamon D; Minarovits-Kormuta S; Schwarzmann F; Wolf H; Niller HH; Minarovits J
Virus Genes; 2007 Oct; 35(2):195-202. PubMed ID: 17510783
[TBL] [Abstract][Full Text] [Related]
30. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.
Sample J; Henson EB; Sample C
J Virol; 1992 Aug; 66(8):4654-61. PubMed ID: 1321268
[TBL] [Abstract][Full Text] [Related]
31. Deletion of Epstein-Barr virus regulatory sequences upstream of the EBNA gene promoter Wp1 is unfavorable for B-Cell immortalization.
Yoo LI; Woloszynek J; Templeton S; Speck SH
J Virol; 2002 Nov; 76(22):11763-9. PubMed ID: 12388739
[TBL] [Abstract][Full Text] [Related]
32. oriP is essential for EBNA gene promoter activity in Epstein-Barr virus-immortalized lymphoblastoid cell lines.
Puglielli MT; Woisetschlaeger M; Speck SH
J Virol; 1996 Sep; 70(9):5758-68. PubMed ID: 8709191
[TBL] [Abstract][Full Text] [Related]
33. EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif.
Ling PD; Ryon JJ; Hayward SD
J Virol; 1993 Jun; 67(6):2990-3003. PubMed ID: 8388484
[TBL] [Abstract][Full Text] [Related]
34. Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element.
Wang F; Kikutani H; Tsang SF; Kishimoto T; Kieff E
J Virol; 1991 Aug; 65(8):4101-6. PubMed ID: 1649318
[TBL] [Abstract][Full Text] [Related]
35. The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein.
Ling PD; Rawlins DR; Hayward SD
Proc Natl Acad Sci U S A; 1993 Oct; 90(20):9237-41. PubMed ID: 8415684
[TBL] [Abstract][Full Text] [Related]
36. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter.
Sjöblom A; Jansson A; Yang W; Laín S; Nilsson T; Rymo L
J Gen Virol; 1995 Nov; 76 ( Pt 11)():2679-92. PubMed ID: 7595375
[TBL] [Abstract][Full Text] [Related]
37. Transcriptional regulatory properties of Epstein-Barr virus nuclear antigen 3C are conserved in simian lymphocryptoviruses.
Zhao B; Dalbiès-Tran R; Jiang H; Ruf IK; Sample JT; Wang F; Sample CE
J Virol; 2003 May; 77(10):5639-48. PubMed ID: 12719556
[TBL] [Abstract][Full Text] [Related]
38. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA.
Ambinder RF; Shah WA; Rawlins DR; Hayward GS; Hayward SD
J Virol; 1990 May; 64(5):2369-79. PubMed ID: 2157891
[TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus EBNA3C represses Cp, the major promoter for EBNA expression, but has no effect on the promoter of the cell gene CD21.
Radkov SA; Bain M; Farrell PJ; West M; Rowe M; Allday MJ
J Virol; 1997 Nov; 71(11):8552-62. PubMed ID: 9343213
[TBL] [Abstract][Full Text] [Related]
40. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection.
Woisetschlaeger M; Jin XW; Yandava CN; Furmanski LA; Strominger JL; Speck SH
Proc Natl Acad Sci U S A; 1991 May; 88(9):3942-6. PubMed ID: 1850841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
